Manulife (Manufacturers Life Insurance)
CRSP icon

Manulife (Manufacturers Life Insurance)’s CRISPR Therapeutics CRSP Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Sell
40,825
-2,952
-7% -$156K ﹤0.01% 1551
2026
Q1 		$2.08M Buy
43,777
+2,247
+5% +$119K ﹤0.01% 1481
2025
Q4 		$2.18M Sell
41,530
-480
-1% -$28.7K ﹤0.01% 1482
2025
Q3 		$2.72M Buy
42,010
+2,697
+7% +$155K ﹤0.01% 1408
2025
Q2 		$1.91M Buy
39,313
+28,410
+261% +$1.1M ﹤0.01% 1517
2025
Q1 		$371K Sell
10,903
-1,387
-11% -$58.8K ﹤0.01% 2270
2024
Q4 		$484K Sell
12,290
-187
-1% -$8.83K ﹤0.01% 2259
2024
Q3 		$586K Buy
12,477
+231
+2% +$11.7K ﹤0.01% 2196
2024
Q2 		$661K Sell
12,246
-8,126
-40% -$470K ﹤0.01% 2083
2024
Q1 		$1.39M Sell
20,372
-9,149
-31% -$655K ﹤0.01% 1669
2023
Q4 		$1.85M Buy
29,521
+128
+0.4% +$7.08K ﹤0.01% 1492
2023
Q3 		$1.33M Buy
29,393
+6,985
+31% +$361K ﹤0.01% 1587
2023
Q2 		$1.26M Buy
22,408
+1,929
+9% +$109K ﹤0.01% 1553
2023
Q1 		$926K Buy
20,479
+161
+0.8% +$7.82K ﹤0.01% 1679
2022
Q4 		$820K Buy
20,318
+527
+3% +$28K ﹤0.01% 1711
2022
Q3 		$1.28M Sell
19,791
-48
-0.2% -$3.48K ﹤0.01% 1507
2022
Q2 		$1.25M Buy
19,839
+4,040
+26% +$238K ﹤0.01% 1551
2022
Q1 		$1.01M Buy
+15,799
New +$992K ﹤0.01% 1745

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s CRSP Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its CRISPR Therapeutics (CRSP) stake by 6.7% in Q2 2026, selling an estimated $156K and leaving 40,825 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Manulife (Manufacturers Life Insurance) first reported a position in CRSP in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.72M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 40,825 shares of CRISPR Therapeutics worth $2.23M as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) sold 2,952 CRISPR Therapeutics shares in Q2 2026, an estimated $156K.
  • CRISPR Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #1551 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Manulife (Manufacturers Life Insurance)'s CRISPR Therapeutics position peaked at $2.72M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.